|
EP0180398A1
(en)
|
1984-10-26 |
1986-05-07 |
The Regents Of The University Of California |
Synthesis of beta-lactam
|
|
CA1305177C
(en)
|
1987-06-30 |
1992-07-14 |
Yasufumi Ohfune |
Carboxycyclopropylglycine and process for producing the same
|
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
|
EP0360390A1
(en)
|
1988-07-25 |
1990-03-28 |
Glaxo Group Limited |
Spirolactam derivatives
|
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
|
CA2058975C
(en)
|
1990-10-30 |
2000-06-06 |
Shuichi Kasai |
Antiinflammatory gel preparation
|
|
US5168103A
(en)
|
1991-01-22 |
1992-12-01 |
American Home Products Corporation |
[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
|
|
FR2692268B1
(fr)
|
1992-06-15 |
1994-08-19 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
|
|
SE9301667D0
(sv)
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
|
US5523323A
(en)
|
1993-09-14 |
1996-06-04 |
Maccecchini; Maria-Luisa |
Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
|
|
US5605911A
(en)
|
1995-01-31 |
1997-02-25 |
Washington University |
Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
|
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5763393A
(en)
|
1996-05-17 |
1998-06-09 |
Neurotherapeutics L.P. |
Neuroactive peptides
|
|
ATE283278T1
(de)
|
1996-06-07 |
2004-12-15 |
Astrazeneca Ab |
Peptid derivate
|
|
JP2000503860A
(ja)
|
1996-08-02 |
2000-04-04 |
ザイモジェネティクス，インコーポレイティド |
精巣―特異的インシュリン同族体ポリペプチド
|
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
|
JP3955345B2
(ja)
|
1996-09-27 |
2007-08-08 |
サントリー株式会社 |
新規アミノ酸ダイジハーベイン
|
|
WO1999024584A1
(en)
|
1997-11-12 |
1999-05-20 |
Neurotherapeutics |
Methods for the detection and treatment of disease using a glycosyltransferase
|
|
US5952389A
(en)
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
|
US6274314B1
(en)
|
1998-04-02 |
2001-08-14 |
Nyxis Neurotherapies, Inc. |
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
|
US6197820B1
(en)
|
1998-04-06 |
2001-03-06 |
Uab Research Foundation |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
|
|
US6025471A
(en)
|
1998-06-03 |
2000-02-15 |
Deghenghi; Romano |
Diazaspiro, azepino and azabicyclo therapeutic peptides
|
|
WO2000027790A1
(en)
|
1998-11-11 |
2000-05-18 |
Smithkline Beecham P.L.C. |
Mutilin compounds
|
|
AU1724000A
(en)
|
1998-11-12 |
2000-05-29 |
Nyxis, Inc. |
Diagnostic assay for cancer
|
|
US20030064921A1
(en)
|
1999-10-27 |
2003-04-03 |
The Regents Of The University Of California |
Methods and compounds for modulating melanocortin receptor ligand binding and activity
|
|
AU1922301A
(en)
|
1999-11-17 |
2001-05-30 |
Nyxis Neurotherapies, Inc. |
Differential gene expression in cancer
|
|
US6521414B2
(en)
|
2000-02-01 |
2003-02-18 |
Agy Therapeutics, Inc. |
Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1
|
|
JP2001261679A
(ja)
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
|
|
WO2001096606A2
(en)
|
2000-06-14 |
2001-12-20 |
Nyxis Neurotherapies, Inc. |
Identification of genes and compounds for treatment of cancer
|
|
AU2001271366A1
(en)
|
2000-06-22 |
2002-01-02 |
Nyxis Neurotherapies, Inc. |
Neuroactive peptides for treatment of hypoxia and related conditions
|
|
GB0018272D0
(en)
|
2000-07-25 |
2000-09-13 |
Vernalis Research Limited |
Chemical compounds IV
|
|
EP1186303A3
(en)
|
2000-09-06 |
2003-12-10 |
Pfizer Products Inc. |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
|
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
|
AU2002236608A1
(en)
|
2000-12-14 |
2002-06-24 |
Nyxis Neurotherapies, Inc. |
High throughput assay to detect inhibitors of the map kinase pathway
|
|
US20030065138A1
(en)
|
2001-03-07 |
2003-04-03 |
University Of Utah Research Foundation |
Linear gamma-carboxyglutamate rich conotoxins
|
|
AU2002255705A1
(en)
|
2001-03-12 |
2002-09-24 |
Nyxis Neurotherapies, Inc |
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
|
US20030022253A1
(en)
|
2001-07-25 |
2003-01-30 |
Nyxis Neurotherapies, Inc. |
Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
|
|
ES2355157T3
(es)
|
2002-07-05 |
2011-03-23 |
Targacept, Inc. |
Compuestos diazaspirocíclico n-arilo y métodos de preparación y uso de las mismas.
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
WO2005007656A1
(en)
|
2003-07-18 |
2005-01-27 |
Virochem Pharma Inc. |
Spiro compounds and methods for the modulation of chemokine receptor activity
|
|
CA2534909A1
(en)
|
2003-08-08 |
2005-02-17 |
The Burnham Institute |
P16 mediated regulation of nmda receptors
|
|
US7662856B2
(en)
|
2003-08-29 |
2010-02-16 |
The University Of Houston System |
Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
|
|
GB0323204D0
(en)
|
2003-10-03 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
|
WO2005047286A1
(ja)
|
2003-11-13 |
2005-05-26 |
Ono Pharmaceutical Co., Ltd. |
スピロ複素環化合物
|
|
DE602004031560D1
(de)
|
2004-01-08 |
2011-04-07 |
Hoffmann La Roche |
Diazaspiropiperidinderivate
|
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
|
CN101090902B
(zh)
|
2004-10-13 |
2013-05-29 |
默沙东公司 |
Cgrp受体拮抗剂
|
|
US20090221544A1
(en)
|
2005-03-24 |
2009-09-03 |
Emory University |
Methods for the treatment of a traumatic central nervous system injury via a tapered administration protocol
|
|
JP5261178B2
(ja)
|
2005-08-26 |
2013-08-14 |
ウィスコンシン アルムニ リサーチ ファンデイション |
官能化されたベータラクタムモノマーからのポリ−ベータ−ペプチド及びポリ−ベータ−ペプチドを含有する抗菌組成物
|
|
AR059224A1
(es)
|
2006-01-31 |
2008-03-19 |
Jerini Ag |
Compuestos para la inhibicion de integrinas y uso de estas
|
|
WO2007103719A2
(en)
|
2006-03-03 |
2007-09-13 |
Incyte Corporation |
MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
|
|
US7884080B2
(en)
|
2006-09-15 |
2011-02-08 |
Schering Plough Corporation |
Azetidinone derivatives and methods of use thereof
|
|
JP2008188285A
(ja)
|
2007-02-06 |
2008-08-21 |
Bridgestone Corp |
バックパッド及び車両用シート
|
|
CN101066945B
(zh)
|
2007-05-25 |
2010-05-19 |
中国科学院上海有机化学研究所 |
一种合成3-位取代内酰胺类化合物的方法
|
|
CN101125817B
(zh)
|
2007-08-03 |
2011-09-14 |
中国科学院上海有机化学研究所 |
一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
|
|
US20090054392A1
(en)
|
2007-08-20 |
2009-02-26 |
Wyeth |
Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
|
|
WO2009039390A2
(en)
|
2007-09-20 |
2009-03-26 |
Naurex Inc. |
The development of glycobiology-based therapeutics for the treatment of brain tumors
|
|
CA2716375C
(en)
|
2008-02-20 |
2018-05-29 |
The Children's Hospital Of Philadelphia |
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
|
|
EP2293777B1
(en)
|
2008-06-24 |
2015-02-25 |
Intervet International B.V. |
Pharmaceutical transdermal compositions and method for treating inflammation in cattle
|
|
CN102076679A
(zh)
|
2008-06-27 |
2011-05-25 |
神经研究公司 |
新颖的四甲基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途
|
|
AU2009278075B2
(en)
|
2008-08-07 |
2013-07-04 |
F. Hoffmann-La Roche Ag |
Process for the preparation of a macrocycle
|
|
GB0814991D0
(en)
|
2008-08-15 |
2008-09-24 |
Glaxo Group Ltd |
Compounds
|
|
MX2011003015A
(es)
|
2008-09-18 |
2011-11-18 |
Univ Northwestern |
Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
|
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
|
DE102009001460B4
(de)
|
2009-03-11 |
2010-12-02 |
Zf Friedrichshafen Ag |
Ölbehälter
|
|
US8329904B2
(en)
|
2009-05-12 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
|
WO2011003064A2
(en)
|
2009-07-02 |
2011-01-06 |
Naurex, Inc. |
Methods of treating neuropathic pain
|
|
PT2985032T
(pt)
|
2009-10-05 |
2019-04-24 |
Univ Northwestern |
Glyx para utilização no tratamento da doença de alzheimer, doença de parkinson ou doença de huntington
|
|
US8951968B2
(en)
|
2009-10-05 |
2015-02-10 |
Northwestern University |
Methods of treating depression and other related diseases
|
|
US8871208B2
(en)
|
2009-12-04 |
2014-10-28 |
Abbvie Inc. |
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
|
|
RU2566821C2
(ru)
|
2010-02-11 |
2015-10-27 |
Нортвестерн Юниверсити |
Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение
|
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
US8097634B2
(en)
|
2010-04-15 |
2012-01-17 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
|
CN102267995A
(zh)
|
2010-06-04 |
2011-12-07 |
艾琪康医药科技（上海）有限公司 |
一种制备二氮杂螺环化合物的方法
|
|
WO2012021712A1
(en)
|
2010-08-12 |
2012-02-16 |
Tetraphase Pharmaceuticals, Inc. |
Tetracycline analogs
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
GEP20156347B
(en)
|
2011-03-14 |
2015-08-10 |
Boehringer Ingelheim Int |
Benzodioxane inhibitors of leukotriene production
|
|
AU2012249397B2
(en)
|
2011-04-27 |
2017-03-30 |
Northwestern University |
Methods of treating Alzheimer's disease, Huntington's disease, autism, or other disorders
|
|
JP6388536B2
(ja)
|
2011-06-27 |
2018-09-12 |
コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． |
超音波振動子アセンブリ及びその製造方法
|
|
JP5427321B2
(ja)
|
2011-07-27 |
2014-02-26 |
アストラゼネカ アクチボラグ |
２−（２，４，５−置換−アニリノ）ピリミジン化合物
|
|
BR112015018094A2
(pt)
|
2013-01-29 |
2017-07-18 |
Naurex Inc |
moduladores de receptor nmda de espiro-lactama e usos dos mesmos
|
|
PE20151427A1
(es)
|
2013-01-29 |
2015-10-10 |
Naurex Inc |
Moduladores de receptores nmda de espiro-lactama y sus usos
|
|
MX2015009778A
(es)
|
2013-01-29 |
2016-02-09 |
Aptinyx Inc |
Moduladores de receptores nmda de espiro-lactama y sus usos.
|
|
BR112015018092A2
(pt)
*
|
2013-01-29 |
2017-07-18 |
Naurex Inc |
moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
|
|
PT2951183T
(pt)
|
2013-01-29 |
2019-06-17 |
Aptinyx Inc |
Moduladores espirolactamas de um recetor nmda e as suas utilizações
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
GB201416346D0
(en)
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
|
AU2017267708B2
(en)
|
2016-05-19 |
2020-02-20 |
Aptinyx Inc. |
Spiro-lactam NMDA receptor modulators and uses thereof
|
|
WO2017201285A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
|
CN109906218B
(zh)
|
2016-08-01 |
2023-01-17 |
阿普廷伊克斯股份有限公司 |
螺-内酰胺nmda受体调节剂及其用途
|
|
AU2017306152A1
(en)
|
2016-08-01 |
2019-01-31 |
Aptinyx Inc. |
Spiro-lactam NMDA receptor modulators and uses thereof
|
|
MX388786B
(es)
|
2016-08-01 |
2025-03-20 |
Aptinyx Inc |
Moduladores nmda espiro-lactam y métodos de uso de los mismos.
|
|
CN109661398B
(zh)
|
2016-08-01 |
2022-07-05 |
阿普廷伊克斯股份有限公司 |
螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
|
|
CA3031539C
(en)
|
2016-08-01 |
2023-11-28 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
|
KR20200115610A
(ko)
|
2018-01-31 |
2020-10-07 |
앱티닉스 인크. |
스피로-락탐 nmda 수용체 조정제 및 그의 용도
|
|
CN112204031B
(zh)
|
2018-01-31 |
2024-05-24 |
元羿生物科技(香港)有限公司 |
螺-内酰胺nmda受体调节剂及其用途
|
|
US12012413B2
(en)
|
2019-11-11 |
2024-06-18 |
Tenacia Biotechnology (Hong Kong) Co., Limited |
Methods of treating painful diabetic peripheral neuropathy
|
|
US20210308101A1
(en)
|
2019-11-11 |
2021-10-07 |
Aptinyx Inc. |
Methods of treating fibromyalgia
|
|
WO2021112987A1
(en)
|
2019-12-04 |
2021-06-10 |
Aptinyx Inc. |
Methods of treating cognitive impairment associated with neurodegenerative disease
|